Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

NCT02022254 · Completed

Last updated 2026-05-28

This clinical trial tested how the diabetes medication semaglutide affects the levels of warfarin and metformin in the blood of healthy adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 24 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2013-12 · est. completion 2014-08

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02022254 ↗

Description as written by the study sponsor.

This trial is conducted in Europe and Asia. The aim of the trial is to investigate the influence of semaglutide on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin and pharmacokinetics of metformin in healthy subjects.

Treatments tested

semaglutide Drug

Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
placebo Drug

Semaglutide placebo will be administered s.c.
metformin Drug

For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
warfarin Drug

For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.

Main thing measured	Area under the metformin plasma concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02022254 ↗